THEODORE J STANDIFORD, MD
Osteopathic Medicine in Ann Arbor, MI

License number
Michigan 4301053979
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Michigan 4301053979
Category
Osteopathic Medicine
Type
Critical Care Medicine
License number
Michigan 4301053979
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
1500 Floor Taubman Ctr, Ann Arbor, MI 48109
Phone
(734) 647-9342
(734) 936-2047

Personal information

See more information about THEODORE J STANDIFORD at radaris.com
Name
Address
Phone
Theodore Standiford, age 66
2981 Devonshire Rd, Ann Arbor, MI 48104
(734) 395-5905
Theodore Standiford
2981 Devonshire Rd, Ann Arbor, MI 48104
(734) 769-5456

Professional information

Theodore J Standiford Photo 1

Dr. Theodore J Standiford, Ann Arbor MI - MD (Doctor of Medicine)

Specialties:
Critical Care Medicine, Pulmonology
Address:
University Michigan Hospital PCC
1500 E Medical Center Dr, Ann Arbor 48109
(734) 763-2540 (Phone)
Certifications:
Critical Care Medicine, 1991, Internal Medicine, 1987, Pulmonary Disease, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
University Michigan Hospital PCC
1500 E Medical Center Dr, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
Education:
Medical School
Wayne State University School Of Medicine
Graduated: 1984
University Of Minnesota
Graduated: 1987
Graduated: 1989


Theodore Standiford Photo 2

Theodore Standiford, Ann Arbor MI

Specialties:
Internal Medicine, Pulmonary Disease, Critical Care Medicine
Work:
Va Ann Arbor Healthcare System
2215 Fuller Rd, Ann Arbor, MI 48105 University of Michigan Medical School
1500 E Medical Center Dr, Ann Arbor, MI 48109
Education:
Wayne State University (1984)


Theodore Standiford Photo 3

Administration Of Products Of The 5-Lipoxygenase Metabolic Pathway To Enhance Antimicrobial Defense

US Patent:
2005026, Dec 1, 2005
Filed:
Jan 19, 2005
Appl. No.:
11/038883
Inventors:
Marc Peters-Golden - Ann Arbor MI, US
Theodore Standiford - Ann Arbor MI, US
International Classification:
A61K031/202
US Classification:
514560000
Abstract:
The use of leukotrienes and other products of the 5-lipoxygenase pathway to enhance bacterial defense and treat infections is described. The products are especially useful when administered to the lungs for the treatment of pneumonia and other lower respiratory tract infections. The products may be administered for treatment or prophylactic purposes and may be administered concomitantly with antibiotics to combat infection.


Theodore Standiford Photo 4

Administration Of Products Of The 5-Lipoxygenase Metabolic Pathway To Enhance Antimicrobial Defense

US Patent:
7696148, Apr 13, 2010
Filed:
Mar 3, 1999
Appl. No.:
09/291656
Inventors:
Marc Peters-Golden - Ann Arbor MI, US
Theodore Standiford - Ann Arbor MI, US
Assignee:
Board of Trustees of Michigan State University - East Lansing MI
International Classification:
C07K 14/00
US Classification:
514 2, 530300, 530350
Abstract:
The use of leukotrienes and other products of the 5-lipoxygenase pathway to enhance bacterial defense and treat infections is described. The products are especially useful when administered to the lungs for the treatment of pneumonia and other lower respiratory tract infections. The products may be administered for treatment or prophylactic purposes and may be administered concomitantly with antibiotics to combat infection.


Theodore Standiford Photo 5

Administration Of Products Of The 5-Lipoxygenase Metabolic Pathway To Enhance Antimicrobial Defense

US Patent:
5909734, Jun 8, 1999
Filed:
Dec 3, 1996
Appl. No.:
8/757136
Inventors:
Marc Peters-Golden - Ann Arbor MI
Theodore Standiford - Ann Arbor MI
Assignee:
Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61B 1900, A61K 704
US Classification:
128898
Abstract:
The use of leukotrienes and other products of the 5-lipoxygenase pathway to enhance bacterial defense and treat infections is described. The products are especially useful when administered to the lungs for the treatment of pneumonia and other lower respiratory tract infections. The products may be administered for treatment or prophylactic purposes and may be administered concomitantly with antibiotics to combat infection.